Sign in

Innova Captab IPO opens for subscription. Check price band, GMP

Innova Captab IPO comprises equity shares of up to 320 crore and an offer-for-sale of up to 55.80 lakh equity shares by promoters and selling shareholders.

Published on: Dec 21, 2023, 09:16:49 IST
Share
Share via
  • facebook
  • twitter
  • linkedin
  • whatsapp
Copy link
  • copy link

Pharmaceutical company Innova Captab opened its initial public offering (IPO) for subscription on Friday. The issue will be open for subscription till December 26.

The company has fixed a price band of 426-448 per share for its IPO worth 570 crore. The IPO comprises equity shares worth up to 320 crore and an offer-for-sale (OFS) of up to 55.80 lakh equity shares by promoters and selling shareholders.

An offer-for-sale is a method in which the promoters in public companies can sell their shares and reduce their holdings in a transparent manner through the bidding platform for the exchange.

Innova Captab is an integrated pharmaceutical company with a presence across the pharmaceuticals value chain, including research and development, manufacturing, drug distribution, and marketing and exports
Innova Captab is an integrated pharmaceutical company with a presence across the pharmaceuticals value chain, including research and development, manufacturing, drug distribution, and marketing and exports

Those selling shares in this offer-for-sale include Vinay Kumar Lohariwala, Manoj Kumar Lohariwala and Gian Parkash Aggarwal. At the upper end of the price band, the IPO is likely to fetch 570 crore.

Inox India IPO listing on share market. Follow LIVE updates

Innova Captab IPO GMP

In the grey market, the shares of Innova Captab are trading at a premium of 211. The estimated listing price is said to be 659, 47.10 per cent more than the issue price.

How will Innova Captab utilise funds raised from IPO?

The company plans to utilise funds worth 144.40 crore raised from the IPO for debt payment, 23.60 crore for investment in the subsidiary UML, and 72 crore for funding working capital requirements.

Innova Captab is an integrated pharmaceutical company with a presence across the pharmaceuticals value chain, including research and development, manufacturing, drug distribution, and marketing and exports.

Innova Captab's consolidated revenue from operations grew 15.72 per cent to 926.38 crore for fiscal 2023 from 800.53 crore in the preceding fiscal.

Its profit after tax rose 6.26 per cent to 67.95 crore for fiscal 2023 from 63.95 crore in FY2022. ICICI Securities and JM Financial are book-running lead managers for the IPO. The equity shares are proposed to be listed on BSE and NSE.

  • Aryan Prakash
    ABOUT THE AUTHOR
    Aryan Prakash

    A journalist with more than 12 years of experience in print, broadcast and digital media. When not tracking major news events, he can be seen binge watching his favourite shows or reading a spy thriller.Read More